Everolimus plus Lenvatinib versus Everolimus for bone sarcoma
Treatments studied
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests whether adding lenvatinib (a targeted cancer drug) to everolimus (an immunosuppressant that fights cancer) works better than everolimus alone for advanced bone cancers like osteosarcoma, Ewing sarcoma, or chondrosarcoma that have progressed despite prior chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with advanced osteosarcoma, Ewing sarcoma, or chondrosarcoma that has been confirmed by a pathologist (tissue sample under a microscope)
- Have received 1 or 2 prior chemotherapy treatments (including neoadjuvant or adjuvant chemotherapy, which are given before or after surgery)
- Age 19–79 years old
- Good enough health to carry out daily activities with minimal help (ECOG performance status 0–1)
- Have at least one measurable tumor that can be tracked on imaging
- Blood counts and organ function (liver, kidney) in acceptable range
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether adding everolimus to chemotherapy (chosen by the treating team) can improve outcomes in advanced triple-negative breast cancer, specifically a subtype linked to PAM pathway changes. It may help patients who have not yet had treatment for advanced/metastatic disease.
This Phase 2 trial tests whether adding everolimus to standard first-line hormone (endocrine) therapy can better control a certain type of advanced breast cancer. It is designed for people whose tumor matches a specific “SNF1 subtype.”
This trial tests a combination of two drugs — voronib and everolimus — for people with clear cell kidney cancer whose previous targeted therapy and immunotherapy have stopped working. The goal is to see if this new combination can help when other treatments have failed.
This early-phase study tests whether adding losartan to sunitinib can help control osteosarcoma that has returned or keeps growing after at least one prior treatment. It may help by targeting the cancer’s growth signals and blood supply, but the goal at this stage is mainly to check safety and find workable dosing.
This trial tests lenvatinib to shrink or control advanced bone or soft tissue sarcoma that can’t be safely treated with surgery. You may be eligible if your cancer has measurable spots and you’ve had specific prior drug treatments without a durable response.
This trial compares two daily doses (5 mg vs 10 mg) of everolimus, a targeted therapy, to see which works better and is safer for people with advanced neuroendocrine tumors (NETs). You may qualify if your cancer has grown despite previous treatment and you are in relatively good health.
Hear when a new Neoplasms of Bone and Articular Cartilage With Unspecified Anatomical Site trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.